CURX.US Curanex Pharmaceuticals Inc Common Stock
- Market cap
- USD 7.53M
- P/E
- -
- P/B
- 1.86x
- ROE
- -484.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CURX.US undervalued?
Graham numberThe Graham number of Curanex Pharmaceuticals Inc Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Curanex Pharmaceuticals Inc Common Stock fundamental analysis
No fundamental analysis for Curanex Pharmaceuticals Inc Common Stock yet.
Curanex Pharmaceuticals Inc Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharma…
Full company profileCuranex Pharmaceuticals Inc Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Curanex Pharmaceuticals Inc Common Stock annual financial statements
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 26.0K | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 4.43K | 0.00 | - | - | - |
| Operating Income | -20.2K | -19.3K | -365K | -4.24M | -12.5M |
| EBITDA | 925.00 | -17.5K | -290K | -4.14M | -12.3M |
| Net Income | -20.2K | -19.2K | -362K | -4.23M | -12.3M |
| EPS | -0.01 | -0.01 | -0.26 | -2.98 | -8.14 |
| Balance Sheet | |||||
| Total Assets | 10.2K | 74.4K | 518K | 11.6M | 3.10M |
| Total Liabilities | 0.00 | 14.3K | 14.6K | 361K | 552K |
| Shareholders' Equity | 10.2K | 60.1K | 503K | 11.2M | 2.55M |
| Cash & Short-term Investments | 2.43K | 74.4K | 149K | 4.97M | 1.58M |
| Total Debt | - | - | - | 347K | 542K |
| Cash Flow | |||||
| Operating Cash Flow | 3.34K | -120.00 | -556K | -10.5M | -4.52M |
| Capital Expenditure | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 |
| Free Cash Flow | 3.34K | -120.00 | -556K | -10.5M | -4.52M |
| Ratios | |||||
| ROE | -197.7% | -31.9% | -71.8% | -37.7% | -484.9% |
| ROA | -197.7% | -25.8% | -69.8% | -36.5% | -398.5% |
| Net Profit Margin | -77.8% | - | - | - | - |
| Debt to Equity | - | - | - | 0.03x | 0.21x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Curanex Pharmaceuticals Inc Common Stock dividends
Curanex Pharmaceuticals Inc Common Stock has not paid dividends in the last 4 fiscal years.
Last stock split: 1:20 on Aug 20, 2026.
Who owns Curanex Pharmaceuticals Inc Common Stock
- Insiders 61.35%
- Institutions 0.60%
- Public & others 38.04%
- Shares outstanding 1.57M
- Free float 506K
Top funds holding CURX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 1.17K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 747.00 | 0.05% | -0.13% | Aug 2026 |
Top institutions holding CURX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 95.3K | 0.30% | +88.41% | Jun 2026 |
| Renaissance Technologies Corp | 52.0K | 0.17% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 51.2K | 0.16% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 38.3K | 0.12% | -65.55% | Jun 2026 |
| Jane Street Group LLC | 31.2K | 0.10% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 27.4K | 0.09% | +35.05% | Jun 2026 |
| Susquehanna International Group, LLP | 14.7K | 0.05% | 0.00% | Jun 2026 |
| Ground Swell Capital, LLC | 12.6K | 0.04% | 0.00% | Jun 2026 |
| Citigroup Inc | 8.96K | 0.03% | -53.67% | Jun 2026 |
| UBS Group AG | 1.51K | 0.00% | -81.16% | Jun 2026 |
| Tower Research Capital LLC | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Jump Financial LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Curanex Pharmaceuticals Inc Common Stock company profile
- Company name
- Curanex Pharmaceuticals Inc Common Stock
- Ticker
- CURX.US
- Exchange
- USA Stocks
- Listed since
- Aug 26, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 2 Jericho Plaza, Jericho, NY, United States, 11753
- Phone
- 718 673 6078
- Website
- curanexpharma.com
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
Curanex Pharmaceuticals Inc Common Stock management
6- Mr. Jun LiuCEO, President & Chairman · born 1964
- Mr. Wanjun ZhangChief Financial Officer & Treasurer · born 1974
- Dr. Liqin Xie Ph.D.Chief Operating Officer · born 1972
- Dr. Ning Zhang Ph.D.Chief Technology Officer · born 1976
- Dr. Huijuan Zhong Ph.D.Chief Science Officer & Director · born 1967
- Ms. Dian Ying JingSecretary · born 1967